BioMarin Pharmaceutical (BMRN) has just released its second quarter 2026 results, giving investors fresh detail on how revenue, earnings and guidance are evolving after its rare disease expansion.

BioMarin Pharmaceutical’s Q2 earnings release and raised guidance have come alongside a 13.69% 90 day share price return and a modest 3.38% year to date share price return, while the 3 year total shareholder return has declined 32.39%, showing that recent momentum contrasts with a weaker longer term record.

If BioMarin’s recent move has you thinking about where growth in healthcare could come from next, it can be useful to scan a wider set of specialised opportunities using 42 healthcare AI stocks

BioMarin Pharmaceutical’s recent share price recovery sits against much weaker 3 year returns, which raises a simple test for investors. Is this move telling a new story about the business, or mainly about sentiment resetting around it?

Most Popular Narrative: 30% Undervalued

Based on the most followed narrative, BioMarin Pharmaceutical’s fair value of $87.85 sits well above the last close at $61.46, which puts the current share price at a clear discount to those assumptions.

Strong year over year revenue growth driven by increasing global demand, new patient starts, and international expansion of key therapies like VOXZOGO and VIMIZIM aligns with demographic shifts and improved rare disease diagnosis, supporting continued top line revenue growth.

Want to see what underpins that gap between price and fair value? The narrative leans on higher growth, rising margins and a different earnings profile than today.

Result: Fair Value of $87.85 (UNDERVALUED)

However, the trajectory of BioMarin Pharmaceutical’s story can change quickly if competition in rare disease treatments intensifies or if key pipeline programs encounter regulatory or clinical setbacks.

Another View On BioMarin Pharmaceutical’s Valuation

While the narrative fair value of $87.85 suggests BioMarin Pharmaceutical looks undervalued, its current P/E of 44.2x tells a very different story. That compares with a fair ratio of 27.6x, a peer average of 21.2x and a US Biotechs industry average of 17.1x, which points to valuation risk if sentiment cools.

For a closer look at what this gap in P/E ratios could mean over time, including how it might close, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment on BioMarin Pharmaceutical pulled between past underperformance and a recent rebound, it makes sense to move quickly and check the numbers for yourself. To see the mix of issues that investors are worried about alongside the potential upsides they are watching, review the 2 key rewards and 2 important warning signs

Looking For More Investment Ideas Beyond BioMarin Pharmaceutical?

If BioMarin Pharmaceutical has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to quickly spot other stocks that might suit your approach.

• Target income potential by reviewing companies in the 9 dividend fortresses if you want stronger cash returns from your portfolio.
• Hunt for value by scanning the 50 high quality undervalued stocks if you prefer a price sensitive investing style.
• Prioritise resilience by checking the 77 resilient stocks with low risk scores if you want steadier risk profiles alongside your higher conviction ideas.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.